Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia
NCT ID: NCT05215015
Last Updated: 2022-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
18 participants
INTERVENTIONAL
2020-11-30
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-CD33/CLL1 CAR-NK Cells
The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
Anti-CD33/CLL1 CAR-NK Cells
The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-CD33/CLL1 CAR-NK Cells
The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who are more than 18 years old (including 18 years old), and less than 75 years old (including 75 years old);
3. Subjects who are diagnosed as AML according to the World Health Organization (WHO) 2016 diagnosis criteria, and meet any of the following:
* Relapsed acute myeloid leukemia: after complete response (CR), there are leukemia cells in peripheral blood or blast cells in bone marrow \>5% (except for other reasons such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration.
* Refractory acute myeloid leukemia: treatment-naive subjects who have no response to the standard of care for 2 courses of treatment; subjects who are relapsed within 12 months with consolidated intensive treatment after CR; subjects who are relapsed after 12 months but have no response to the conventional chemotherapy; subjects who are relapsed twice or more; subjects who have persistent extramedullary leukemia.
4. Subjects who are positive in CD33 or CLL1 test (according to the results of the central laboratory);
5. Subjects are allowed to have received ≤1 autologous HSCT;
6. Subjects whose performance status scores of the Eastern Cooperative Oncology Organization (ECOG) are≤2;
7. Subjects with the expected survival phase\>3 months;
8. Organ function should meet the following criteria:
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN), unless these are caused by leukemia cell infiltration as determined by the investigator;
* Total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN);
* Glomerular filtration rate (GFR)\>50 mL/min;
* Left ventricular ejection fraction (LVEF)≥50%, no clinically significant pericardial effusion confirmed by echocardiography;
* Blood oxygen saturation under indoor ventilation in the screening phase\>92%;
9. Female subjects of childbearing age must be negative in the pregnancy test results in the screening phase;
10. Male and female subjects of childbearing age must agree to take effective birth controls after signing the informed consent forms, during the study, and within 6 months after the last administration.
Exclusion Criteria
2. Subjects who suffer from or are suspected of suffering from central nervous system leukemia, or central nervous system involvement;
3. Subjects who have received allogeneic HSCT;
4. Subjects who have prior II-IV (Glucksberg criteria) acute graft versus-host disease (GvHD) or extensive chronic GvHD;
5. Subjects who have received chimeric antigen receptor cell therapy or other cell therapy;
6. Subjects who have received anti-tumor therapy in the early stage but are not recovered in the toxicity (according to NCI-CTCAE 5.0, the toxicity has not recovered to ≤ Grade 1, except for fatigue, anorexia, and alopecia);
7. Subjects who have had other malignant tumors within 5 years before inclusion, except for any type of carcinoma in situ that has been cured in the past and cured skin basal cell carcinoma or skin squamous cell carcinoma;
8. Subjects whose cardiac function and disease meet one of the following conditions within 6 months before the first administration:
* Any risk factors that increase QTcF (Fridericia formula) interval prolongation, such as uncorrectable hypokalemia, hereditary long QT syndrome, and use of drugs that prolong the QTcF interval;
* New York Heart Association (NYHA) classification ≥Grade 3;
* QTcF interval prolongation (male\>450 milliseconds; female\>470 milliseconds);
* Unstable angina pectoris, and myocardial infarction;
9. Subjects who have a history of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) that require systemic immunosuppressive/systemic disease modulating drugs within 2 years before the first administration;
10. Subjects who have active systemic fungal, bacterial or viral infections that are uncontrolled or are required to be treated by intravenous administration;
11. Subjects with human immunodeficiency virus (HIV) antibody positive;
12. Subjects with HBsAg (-) and HBcAb (-). If subjects have HBsAg (+) and/or HBcAb (+), then subjects with HBV-DNA below the local lower limit of quantification can be included;
13. Subjects with hepatitis C virus antibody (-). If subjects have hepatitis C virus antibody (+), then subjects with HCV-RNA (-) can be included;
14. Female subjects who are breastfeeding and unwilling to stop breastfeeding;
15. Subjects who have received major surgery (for the definition of major surgery, refer to the Level 3 and 4 surgeries specified in the Administrative Measures for the Clinical Application of Medical Technology) within 28 days before the first administration.
16. Subjects who have received a solid organ transplant;
17. Subjects who have a history of alcohol, drug use or drug abuse;
18. Subjects who are known to be allergic to the study drug and/or main components and/or any excipients of the study drug;
19. Subjects who have other severe, acute, or chronic diseases or laboratory abnormalities that may increase the risk of participating in the study and receiving the study drug, or may interfere with the interpretation of study results.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imbioray (Hangzhou) Biomedicine Co., Ltd.
INDUSTRY
Wuxi People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wuxi People's Hospital
Wuxi, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Peihua Lu, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WX-IBR-7
Identifier Type: OTHER
Identifier Source: secondary_id
IBR733-T01
Identifier Type: -
Identifier Source: org_study_id